Centre for Access to Innovative Medicines (A2IM)
The Centre’s mission is to evaluate government policies affecting the availability of new medicines in Canada; and identify policy options for improving patient access. A2IM is funded by corporate sponsorship and sales of employee group subscriptions. Sponsors include research-based pharmaceutical companies.
LEAD RESEARCHER: Brett Skinner PhD
Brett Skinner is the founder and CEO of Canadian Health Policy Institute. Dr. Skinner is a well-known health policy expert, and author of 2 books, over 100 major policy papers, and over 100 opinion editorials. Dr. Skinner has a PhD from Western University, where he lectured in the Faculty of Health Sciences and the Department of Political Science. His extensive leadership experience in policy research and advocacy includes Executive Director of Health and Economic Policy at Innovative Medicines Canada (2013-2017), and CEO (2010-2012) and Director of Health Policy (2004-2012) at Fraser Institute. He is a passionate advocate for policies that promote the development of, and access to innovative medical treatments. In 2015, he was diagnosed with an atypical form of early onset Parkinson’s disease that is non-responsive to existing medications. He has both an academic interest and a personal health stake in government choices affecting future medical innovation.
A2IM research topics:
Public v private insurance coverage for new drugs in Canada, 2018-2023, 7th Edition
Waiting for new medicines in Canada, Europe, and the United States 2018-2023
Patented Medicines Expenditure in Canada 1990–2022 8TH Edition
Patent term erosion and the availability of new medicines in Canada 2000-2022
Rogue Regulator: PMPRB’s false narrative is driving dangerous drug price controls
Prices for Patented Medicines in Canada and 13 Other Countries
Ensuring early access to a COVID-19 vaccine in Canada
Vaccines policy in Canada: International and Domestic Comparisons.
Evidence that regulating pharmaceutical prices negatively affects R&D and access to new medicines.
COVID-19 Economic Costs and the Implicit Value of a Life-Year in Canada
Patented Medicines Costs of Private Insurers: PMPRB Implications.
Potential impact of U.S. demand on the Canadian supply of 46 prescription drugs.
Patented drug prices and clinical trials in 31 OECD countries 2017: implications for Canada’s PMPRB.
HTA and public coverage of new mental health drugs in Quebec and Canada.
Close the Gaps: Patient Benefits and Taxpayer Costs of 3 Pharmacare Options
Evidence that innovative medicines improve health and economic outcomes: focused literature review.
Out-of-pocket prescription drug costs: What are the implications for National Pharmacare?
Taxpayer Cost of National Pharmacare: Disputing the Parliamentary Budget Officer’s Estimate
Prescription drug plan coverage 2016: how many Canadians were insured, under-insured or uninsured?